Aditxt to terminate arrangement agreement with Appili Therapeutics

Stock Information for Aditxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aditxt Inc.

Aditxt Provides Updates on its Growth Vision for bitXbio(TM), Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025
Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market
Evofem Announces Voting Results from Special Meeting of Stockholders
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.